Register Now - Beyond Recruitment: The Future of Patient Site Engagement in Oncology Clinical Trials
|Articles|January 20, 2009

Almac Celebrates 20 Years

Key Almac division celebrates 20 years of growth

Almac Clinical Services now employs 1100 worldwide as it reaches its twentieth year

Almac Clinical Services, one of the key divisions at the Almac Group, has this month reached its twentieth year of operation. The Clinical Services division was founded in 1988 and has grown to become the largest and one of the most successful parts of the Almac family.

Originally operating with two employees in one location in Craigavon, the company now employs 1100 skilled individuals across three main operational centres-Craigavon (UK), Audubon (PA) and Durham (NC) in the US.

Almac Clinical Services has enjoyed exceptional year-on-year growth and continues to out-perform in the clinical supply marketplace in what has become an ever more challenging and competitive environment globally. The ongoing success has been built on a solid platform of providing service excellence to all clients irrespective of size, with Almac’s highly skilled and dedicated staff working within a quality ethos across all sites.

As Almac Clinical Services enters its third decade of operations, the company is now firmly established as a market leader in provision of world-class clinical services. Almac has recently announced further expansion with a new $110m North American Headquarters in the US, which will create hundreds of additional new jobs in Pennsylvania as well as further opportunities for existing staff.

Commenting on this milestone, Almac Clinical Services MD Dr Robert Dunlop said: “When we began trading as Clinical Trial Services, we competed in the market by offering all of our clients exceptional customer service. Although the service we provide has been complemented as technological and other advancements are made, that core commitment to customer services remains as strong as it was twenty years ago.

 “Many of the staff who founded and contributed to the progress of our company are still with us today and have helped ensure Almac Clinical Services continues to occupy the market leading position it acquired many years ago.

“We congratulate all of those who have worked here over the past twenty years, both our dedicated staff and faithful clients alike. I am confident that over the next twenty years and beyond we will continue to develop the services that our market deserves and that our dedication to service will remain as strong as ever,” he added.

About Almac

The Almac Group comprises five closely integrated divisions offering a broad range of services from R&D, translational genomic services, API manufacture, product development, clinical trial supply and technology (IVRS/EDC), to commercial-scale manufacture. Almac provides services to over 600 companies including all the world leaders in the pharmaceutical and biotech sectors.

The company has almost 2,200 employees and is headquartered in Craigavon, Northern Ireland. US operations are based in Pennsylvania, North Carolina and California. Construction of the company's new $100m North American Headquarters started in July 08 and is expected to be completed 2010.

To find out more about Almac visit www.almacgroup.com.


Related to this article

Closing the Community Access Gap: Q&A with Kent Thoelke, Paradigm Health
In this Q&A, Kent Thoelke, CEO of Paradigm Health, discusses why participation gaps in community and rural settings come down to both patient cost barriers and site infrastructure, how legacy workflows weigh on community clinics, and what policy and technology changes it would take to make clinical research a real care option for more patients.
© Grispb - © Grispb - stock.adobe.com
Mistral and OpenAI produced identical overall eligibility labels across 200 synthetic patient-study assessments, with criterion-level disagreements concentrated in inclusion criteria where models switch between “Uncertain” and “Not included” when records lack sufficient evidence, so model choice should be driven by deployment architecture, control, and cost rather than assumed interchangeability.
The Human Side of Clinical Trials: Before Burden Becomes Risk, Capturing Friction in Real Time
In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.